Abbott Laboratories (ABT.N)
84.37USD
22 Aug 2019
-- (--)
$84.37
--
--
--
--
1,475,667
$88.76
$64.48
About
Overall
| Beta: | 1.11 |
| Market Cap(Mil.): | $156,218.30 |
| Shares Outstanding(Mil.): | 1,764.18 |
| Dividend: | 0.32 |
| Yield (%): | 1.45 |
Financials
| ABT.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 53.85 | 33.28 | 33.85 |
| EPS (TTM): | 1.64 | -- | -- |
| ROI: | -- | 14.10 | 12.69 |
| ROE: | -- | 64.83 | 17.13 |
Abbott hits record high as diabetes device fuels profit beat
Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.
Abbott hits record high as diabetes device fuels profit beat
Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.
UPDATE 3-Abbott hits record high as diabetes device fuels profit beat
* Shares rise 4% (Adds details on FreeStyle Libre; Updates shares)
US STOCKS-Wall St flat as railroads slide after CSX signals trade impact
* Dow flat, S&P off 0.05%, Nasdaq 0.06% higher (Updates to open)
Abbott to hike production of lower-cost glucose monitors as diabetes soars
CHICAGO Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.
Abbott to hike production of lower-cost glucose monitors as diabetes soars
CHICAGO Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.
FOCUS- Abbott to hike production of lower-cost glucose monitors as diabetes soars
CHICAGO, July 16 Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.
Abbott device helps in cutting blood sugar in type 2 diabetics: study
Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.
CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)
June 8 Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.
Abbott Labs quarterly beat overshadowed by unchanged forecast
Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.
Estimates